NEW YORK (GenomeWeb) – Med Fusion today announced an agreement with Highmark to provide diagnostic laboratory services for Highmark's commercial and Medicare Advantage plans.

The agreement will allow Highmark members in Pennsylvania and West Virginia to access Med Fusion's reference laboratory services, as well as molecular testing in oncology, women's health, and urology. Highmark is an affiliate of Blue Cross Blue Shield.

Financial details of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.